Program Overview

Chronic hepatitis B (CHB) afflicts 350 million persons worldwide and an estimated 1.25 million individuals in the US. The health and well-being of these patients depends upon their clinician being knowledgeable regarding the signficant advances in the diagnosis and treatment of CHB that have occurred in the past five years. The wide range of clinical manifestations of CHB and the availability of multiple treatment options for CHB significantly increase the importance of clinician education regarding (1) the natural history and epidemiology of CHB, including the effects of genetic diversity of HBV on its natural history, (2) effective strategies for treatment of CHB, including the potential limitations of treatment, for example, the inability to eradicate HBV and the potential for emergence of HBV resistance, and (3) appropriate monitoring strategies for the prevention and early detection of HBV-related complications. This program is designed to provide clinically-relevant education on these and other CHB-related topics in a novel and effective presidential-debate style format which will feature two nationally known and recognized CHB experts.

This tuition-free program is for health care providers who treat CHB patients and there are no prerequisites.

Faculty

Douglas T. Dieterich, MD		Mark Sulkowski, MD
Mount Sinai School of Medicine CME Course Director		Johns Hopkins University School of Medicine CME Course Director
Nezam H. Afdhal, MD		Paul Martin, MD, FACP
Harvard Medical School		University of Miami Miller School of Medicine
Robert S. Brown, Jr., MD, MPH		Fred Poordad, MD
Columbia University Medical Center		David Geffen School of Medicine at UCLA
Steven L. Flamm, MD		Tram T. Tran, MD
Northwestern Feinberg School of Medicine		David Geffen School of Medicine at UCLA
Ira Jacobson, MD		Naoky Tsai, MD
Weill Cornell Medical College		University of Hawaii
Paul Kwo, MD
Indiana University School of Medicine

Learning Objectives

Upon completion of this CME activity, the participant should be able to:

1. Summarize, discuss with colleagues, and apply clinically the most recent and relevant data on the diagnosis, management and treatment of CHB including the use of new diagnostic and monitoring tools and recently approved therapies
2. Assess CHB patients and make an appropriate clinical decision regarding the role of and need for liver biopsy
3. Review patient case scenarios and be able to outline and discuss the factors to consider when deciding on when to start CHB therapy
4. Be aware of and knowledgeable about the risks and benefits of various CHB therapies currently available
5. Assess and explain the potential role of combination therapy in treatment-naïve and treatment-experienced patients
6. Evaluate the potential role for HBV resistance testing and the potential for resistance associated with various CHB treatment strategies in the context of clinical case scenarios

Locations

Meetings are held in private conference facilities at restaurants in each city.  Click the registration button below for details on exact locations.

Tuesday - April 14, 2009		Thursday - June 18, 2009
Boston, MA		San Francisco, CA
Thursday - April 16, 2009		Tuesday - June 23, 2009
Philadelphia, PA		Pasadena, CA
Tuesday - May 12, 2009		Tuesday - June 24, 2009
Manhattan, NY		San Diego, CA
Wednesday - May 13, 2009		Tuesday - June 30, 2009
Queens, NY		Chicago, IL
Tuesday - May 26, 2009		Wednesday - July 1, 2009
Hackensack, NJ		Houston, TX
Wednesday - May 27, 2009		Wednesday - July 8, 2009
Garden City, NY		Miami Beach, FL
Tuesday - June 9, 2009		Tuesday - July 14, 2009
Falls Church, VA		Burlingame, CA
Wednesday - June 10, 2009		Wednesday - July 15, 2009
Baltimore, MD		Anaheim, CA
Tuesday - June 16, 2009		Wednesday - August 3, 2009
Seattle, WA		Honolulu, HI
Wednesday - June 17, 2009		Tuesday - August 4, 2009
San Jose, CA		Honolulu, HI

Accreditation Statement:
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement: The Johns Hopkins University School of Medicine designates this educational activity for a maximum of2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with their extent of participation in the activity.

Policy on Faculty and Provider Disclosure: It is the policy of the Johns Hopkins University School of Medicine that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the course handout materials.

Americans with Disabilities Act: The Johns Hopkins University School of Medicine fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.

Supported by an educational grant from Gilead Sciences

If this message has reached you in error, or you would like to be removed from our mailing list, please reply to this message with the word 'Unsubscribe' in the Subject Line.

ViralEd •112 Dunkard Church Road • Stockton, NJ 08559